NEVVI Medicare utilization intelligence
or

← back

Provider profile

RUDRAPATNA, VENKATESH M.D.

Hematology-Oncology · NPI 1104012996 · AMES, IA

1
Groups
83
Codes · 2024
250,941
Disclosed services

RUDRAPATNA, VENKATESH is a Hematology-Oncology in AMES, IA, a member of 1 medical group, who billed 83 distinct codes to Medicare Part B in 2024.

Groups: MCFARLAND CLINIC PC (AMES, IA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

250,941
disclosed services
83
codes billed to Medicare Part B
Prior year · CY2023 278,506 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
J9271 Injection, pembrolizumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9267 Injection, paclitaxel, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
J9263 Injection, oxaliplatin, 0.5 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
36415 Insertion of needle into vein for collection of blood sample
J1437 Injection, ferric derisomaltose, 10 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J3475 Injection, magnesium sulfate, per 500 mg
83615 Lactate dehydrogenase (enzyme) level
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96413 Administration of chemotherapy into vein, 1 hour or less
83735 Magnesium level
J0640 Injection, leucovorin calcium, per 50 mg
96372 Injection of drug or substance under skin or into muscle
J2405 Injection, ondansetron hydrochloride, per 1 mg
J9045 Injection, carboplatin, 50 mg
J9190 Injection, fluorouracil, 500 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
Q5130 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
96375 Injection of additional new drug or substance into vein
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
84165 Protein measurement, serum
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
82728 Ferritin (blood protein) level
J1200 Injection, diphenhydramine hcl, up to 50 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
83540 Iron level
83550 Iron binding capacity
96415 Administration of chemotherapy into vein, each additional hour
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
96417 Administration of additional new drug or substance into vein, 1 hour or less
85610 Blood test, clotting time
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
84439 Thyroxine (thyroid chemical), free
84443 Blood test, thyroid stimulating hormone (tsh)
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3490 Unclassified drugs
J7030 Infusion, normal saline solution , 1000 cc
82378 Carcinoembryonic antigen (cea) protein level
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
96360 Infusion into a vein for hydration, 31-60 minutes
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
84153 Psa (prostate specific antigen) measurement, total
G0008 Administration of influenza virus vaccine
90662 Influenza vaccine split virus, preservative free
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
82746 Folic acid level, serum
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
82607 Cyanocobalamin (vitamin b-12) level
90480 Admn sarscov2 vacc 1 dose
91322 Sarscov2 vac 50 mcg/0.5ml im
J2997 Injection, alteplase recombinant, 1 mg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
96411 Administration of additional new drug or substance into vein using push technique
96523 Irrigation of implanted venous access drug delivery device
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
85045 Red blood count, automated test
99238 Hospital discharge day management, 30 minutes or less
85007 Microscopic examination for white blood cells with manual cell count
99239 Hospital discharge day management, more than 30 minutes
38222 Biopsy and aspiration of bone marrow sample for diagnosis
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
36593 Declotting of central venous tube
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96361 Infusion into a vein for hydration, each additional hour
86334 Immunologic analysis technique on serum (immunofixation)

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.